Risk factors
Neuphoria Therapeutics (NEUP) risk factors
Item 1A of every Neuphoria Therapeutics Inc. 10-K on file, and what changed from one year to the next.
- FY2026 10-K risk factors
117 risks, 26 new, 9 dropped, 23 reworded since the prior year. A $5.4 million goodwill impairment followed setbacks involving out-licensed assets and could recur if partners suspend development.
Filed Sep 18, 2026 - FY2025 10-K risk factors
100 risks, 28 new, 16 dropped, 26 reworded since the prior year. Neuphoria Therapeutics relies heavily on clinical success, particularly for lead product candidate BNC210, and continued external financing.
Filed Sep 29, 2025 - FY2024 10-K risk factors
88 risks. Neuphoria Therapeutics faces typical clinical-stage biotechnology risks centered on cash burn, clinical trial execution, regulatory approval, and third-party manufacturing dependencies.
Filed Sep 30, 2024